1 of 1
Story summary
- Pfizer's $7.3 billion acquisition of Metsera aims to re-enter the obesity market projected to reach $100 billion by 2030.
- The deal includes a $4.9 billion upfront payment and milestone payments tied to development milestones.
- Metsera's lead MET-097i is a GLP-1 receptor agonist with once-monthly dosing.
- Analysts are cautious, citing integration risks and competition from Eli Lilly and Novo Nordisk.
